Evaluation of absorption, distribution, metabolism, and excretion of [(14)C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors

Rucaparib, a poly(ADP-ribose) polymerase inhibitor, is licensed for use in recurrent ovarian, fallopian tube, or primary peritoneal cancer. We characterized the absorption, distribution, metabolism, and elimination of rucaparib in 6 patients with advanced solid tumors following a single oral dose of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Liao, Mingxiang, Watkins, Simon, Nash, Eileen, Isaacson, Jeff, Etter, Jeff, Beltman, Jeri, Fan, Rong, Shen, Li, Mutlib, Abdul, Kemeny, Vendel, Pápai, Zsuzsanna, van Tilburg, Pascal, Xiao, Jim J.
Format: Artigo
Langue:Inglês
Publié: Springer US 2019
Sujets:
Phase I Studies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7211193/
https://ncbi.nlm.nih.gov/pubmed/31250355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00815-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires